2023
End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. Journal Of Clinical Oncology 2023, 41: 4729-4738. PMID: 37339389, PMCID: PMC10602547, DOI: 10.1200/jco.22.02180.Peer-Reviewed Original ResearchConceptsSystemic treatmentEnd of lifeWhite patientsBlack patientsOdds ratioLarge real-world populationPractice settingsTreatment ratesPatient-level factorsEmergency department useIntensive care unitReal-world populationDay of deathImmunotherapy eraSystemic therapyOncologic treatmentCare unitDeidentified databaseDepartment usePatient raceInsurance typeMetastatic cancerDownstream careMedicaid patientsHigher oddsThe association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM).
Canavan M, Sheth K, Scott J, Westvold S, Adelson K. The association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM). Journal Of Clinical Oncology 2023, 41: 6580-6580. DOI: 10.1200/jco.2023.41.16_suppl.6580.Peer-Reviewed Original ResearchSystemic anticancer therapyDay of deathOncology Care ModelEnd of lifeAcute care useIntensive care unitInpatient admissionsED visitsCare useReceipt of chemotherapyAcute care utilizationEmergency department useProportion of decedentsRates of chemotherapyChi-square testICU stayIO therapyCare unitCare utilizationInpatient stayCT patientsDepartment useHospice useCare metricsOncology practice
2019
Effects of rising drug costs on efforts to control overall cost at a large academic cancer center.
Adelson K, Canavan M, Supalla S, Sedghi T, Chaudhry B, Sinanis N, Gross C. Effects of rising drug costs on efforts to control overall cost at a large academic cancer center. Journal Of Clinical Oncology 2019, 37: 2-2. DOI: 10.1200/jco.2019.37.27_suppl.2.Peer-Reviewed Original ResearchOncology Care ModelLarge academic cancer centerAcute care useAcademic cancer centerPost-acute careMean costCancer CenterCare useDrug costsEmergency department useCost of hospitalizationMean total costValue-based payment programsCost of pharmaceuticalsCancer HospitalCancer careDepartment useTotal episodesInpatient careMedicare claimsCare modelCareEpisodesUtilization categoriesPharmaceutical spending
2016
End-of-Life Care Intensity and Hospice Use
Wang SY, Aldridge MD, Gross CP, Canavan M, Cherlin E, Johnson-Hurzeler R, Bradley E. End-of-Life Care Intensity and Hospice Use. Medical Care 2016, 54: 672-678. PMID: 27111747, PMCID: PMC4907842, DOI: 10.1097/mlr.0000000000000547.Peer-Reviewed Original ResearchConceptsLife care intensityHospital referral regionsShort hospice enrollmentEmergency department useCare intensityHospice useHospice enrollmentDepartment useLife careIntensive care unit admissionOverall hospice useCare unit admissionProportion of decedentsMonths of lifeUnit admissionICU admissionICU daysPatient characteristicsIntensive careLowest quintileReferral regionsIntensive endShort stayAORNumber of days